INTRODUCTION Epidemiology
Ovarian cancer is the ninth most common cancer in women (excluding skin cancer). It ranks fifth as the cause of cancer death in women. A woman's risk of getting invasive ovarian cancer in her lifetime is about 1 in 71 and the lifetime risk of dying from invasive ovarian cancer is about 1 in 95. In the United States, approximately 21,550 new cases and 14,600 deaths are estimated annually [1, 2] . There are, however, large variations in the incidence of ovarian cancer in different areas of the world, in the European Union the estimated number of newly diagnosed cases was 42 .700 in 2004 with a mortality of 12/100000 women/year [3] .
The majority of these deaths were from ovarian cancer of the serous histological type and around half of women who are diagnosed with ovarian cancer are 60 or older.
Genetic predisposition for familial early-onset breast cancer accounts for approximately 5-10% of all breast cancers and 7-10% of all ovarian cancers [4] . Mutations in two autosomal dominant genes, BRCA1 and BRCA2, have been linked to familial breast or breast and ovarian cancer [5, 6] . Women who carry BRCA1 or BRCA2 mutations have an estimated lifetime risk of between 60% and 85% for developing breast cancer, and a lifetime risk of between 26% and 54% for developing ovarian cancer for BRCA1, and between 10% and 23% for BRCA2 [7] [8] [9] [10] .
Although their mechanism of action is not yet fully elucidated, it is assumed that these genes play a key role in important cellular pathways including response to DNA damage, transcription, and interaction with other proteins involved in DNA repair and apoptosis [11, 12] Genetic testing helps in identifying high-risk individuals in families with inherited breast and/or ovarian cancer, and there are various management options available for mutation carriers.
Etiology
Ovarian cancer has been associated with low parity and prognosis, pathology, and underlying molecular genetic alterations [13] . The main reason for the lack of success in effectively treating ovarian cancer is our limited understanding of its etiology and the very few molecular diagnostic markers and therapeutic targets known so far. Identification and characterization of ovarian cancerassociated genes are fundamental for unveiling the pathogenesis of its initiation and progression, especially the development of recurrent diseases. If there was a way to determine "key drivers"
of carcinogenesis which could address this issue, those patients with tumors amenable to surgical cytoreduction could be offered surgery as the initial therapy and the others (suboptimal) could be offered neoadjuvant therapy, followed by surgery. These "key drivers" could represent potential markers for prognosis and therapy. It has been suggested that early genetic events may direct the differentiation of ovarian epithelial cells. Decades of research have investigated molecular events such as: oncogenic activities of KRAS, BRAF, and AKT, and silencing mutations of TP53, RB, and PTEN that lead to ovarian cancer development.
However, this information has had surprisingly little clinical impact on the outcome of women diagnosed with ovarian cancer.
Recent evidence suggests that metastasis is an earlier event than previously thought and that only a very small number of shed malignant cells are capable of metastasizing (0.01%) [14, 15] .
The persistence of cancer cells in the vasculature does not necessarily result in seeding to distant sites and emerging evidence in breast cancer suggests that early tumors may already hold the genetic profile needed for metastasis. These early alterations in dominant genes may dictate the specific path that is followed with K-RAS leading to an LMP tumor and the early occurrence of a P53 or BRCA alteration leading to genetic instability and rapid progression to a high-grade phenotype.
Characteristics common to both pathways include evasion of immune surveillance, invasion into the stroma, survival in the peritoneal cavity, attachment to intraperitoneal sites, and continued growth and angiogenesis [16] . What is urgently needed is an effective approach to rapidly and maximally leverage available ovarian cancer patient data to create an understanding of the disease that is detailed enough and accessible enough to enable "what if" queries regarding how best to treat patients with specific tumor characteristics, in terms of both genetics (the potential for disease outcome), disease biology (how the potential has played out up to the point of measurement), and the connections between these and the clinical outcome, and can, in addition, incorporate the thousands of relevant variables. [18] .
Clinical presentation
Imaging of the ovary has been proposed as a strategy to detect changes in size and architecture that might precede the development of symptoms and detection by pelvic examination.
Transvaginal ultrasonography is superior to transabdominal ultrasonography for detecting subtle details of ovarian structure and size. The use of size and morphologic characteristics of ovarian masses has been proposed to differentiate benign from malignant neoplasms [19] . In one study, in which measurement of ovarian volume, cyst-wall characteristics, and the presence of septae were used to calculate a risk score, the sensitivity was 89% and the specificity was 70%. Another morphologic index was reported to have a sensitivity of 100% and a specificity of 83% in differentiating benign from malignant lesions [20] . On the basis of stringent ultrasonographic criteria (i.e., unilocular ovarian cysts measuring less than 5 cm in diameter were not considered suspicious), the positive predictive value for ultrasonography was 27%, and the sensitivity was 85%. However, the fact that many patients were at high risk suggests that this positive predictive value is higher than the value that would be expected in the general population. Among women whose ovarian cancers were detected by screening, the 5-year survival rate was 77%, as compared with a rate of 49% in a historical control group from the same institution. However, the lack of randomization and an appropriate control group precludes a conclusion that screening resulted in improved survival [21] .
Other imaging techniques, such as magnetic resonance In addition to stage, the extent of residual disease after primary surgery, the volume of ascites, patient age, and performance status are all independent prognostic variables [23] .
Unfortunately, the only factor that the gynaecologist can influence 
Surgical treatment
The standard approach to initial treatment of patients with advanced ovarian cancer (AOC) consist of primary cytoreductive surgery followed by combination platinum-based chemotherapy.
Tumor reduction prior to chemotherapy may synchronize cell division, improve drug availability to metastases, reduce the number of cycles of chemotherapy required to eradicate residual disease, and diminish development of subsequent drug resistance.
Primary cytoreductive surgery has therefore become the cornerstone of the initial approach of patients with AOC. In 1975
Griffiths et colleagues [27] , observed that patients who underwent surgical cytoreduction of bulky disease to small-volume disease had longer survival time than patients with larger-diameter disease. They proposed that their observation supported the Goldie-Coldman hypothesis, which states that small-volume tumors are less likely to develop chemotherapy resistance. Since 1986 the Gynecologic Oncology Group (GOG) has used the threshold of ≤1 cm residual disease in greatest dimension to define "optimal" cytoreduction [23, 28] , recently several reports have demonstrated that there may be an additional survival advantage associated with cytoreduction to no visible residual disease [29] [30] [31] [32] [33] [34] .
A literature review showed that patients with optimal cytoreduction had a median survival of 39 months compared with survival of only 17 months in patients with suboptimal residual disease. Hoskins et al., who presented data from the GOG showed that patients whose largest residual lesions were no greater than 10 mm had a superior survival [35] . Clearly, those patients whose disease has been completely resected have the best prognosis, and approximately 60% of patients in this category were free of disease at 5 years. Bristow et al. evaluated 81 studies involving 6885 patients and demonstrated that each 10% increase in the number of patients receiving maximal cytoreduction was associated with a 5.5% increase in median survival [36] .
Unfortunately many women with ovarian cancer do not undergo optimal surgery, one of the main reason is explained by numerous studies that have shown optimal cytoreduction rates grater than 50% often require the incorporation of a variety of extensive upper abdominal surgical procedures, not always affordable by general gynaecologists. Recently, accumulated evidence has suggested an associated survival benefit to these interventions in appropriate patients. Eisenhauer et al. [37] showed that in patients with stage IIIC and IV ovarian carcinoma who were optimally cytoreduced with the utilization of extensive upper abdominal surgery as diaphragm peritonectomy and/or resection, splenectomy, distal pancreatectomy, liver resection, etc., had improved survival compared to those who had suboptimal cytoreduction. Moreover, the PFS and OS of those patients who needed extensive upper abdominal procedures was identical to that of those who had less tumor volume and were able to be optimally cytoreduced with less-extensive surgery.
Studies have consistently shown that specialized surgeons, gynecologic oncologists, are more likely than general surgeons to perform optimal surgery for ovarian cancer [38] .
The use of more extensive surgical approach has been associated with longer operative times, increased blood loss and transfusions, as well as higher morbidity [39] .
Some investigators, such as Vergote et al. [40] Although a poor performance status, stage IV disease, and large number of metastatic implants on the mesenteric surface reduced the probability of achieving complete cytoreduction, the majority of patients with these findings still can undergo complete cytoreduction. Hence, it seems very difficult to define a group of patients for whom maximal operative effort would be impractical.
Concerns about operative morbidity, reporting of outcomes that antedate descriptions of techniques that are necessary to achieve complete cytoreduction, and differences of opinion regarding the (Table   1 ). Lymph node dissection (pelvic and/or para-aortic) was performed in 178/240 (74%) of the patients and 65% of these patients had positive lymph nodes at final pathology. Ascites was present at the time of surgery in 171 patients (71%) with a volume ranging between 100 cc and 15000 cc. Peritoneal carcinomatosis was present in 170/240 (71%), the majority of the patients presented the largest tumor mass at the level of pelvis, the median size was 13 cm with a range between 3 cm and 40 cm ( Table 2 ).
All surgical procedures are listed on Table 3 Table   4 ).
The median EBL was 700 cc (range100 cc to 6000 cc) and the median operative time was 270 minutes (range 75 minutes to 480 minutes). 104 patients (43%) were transferred to the surgical intensive care unit post-operatively, with a median stay in the intensive care unit of 1 day (range 1 to 10 days). Blood transfusion, either intra-operatively or post-operatively, was administered to 157 (65%) of patients. Post-operative total parenteral nutrition was administered to 112/240 (47%) cases (Table 4) .
There was no intra-operative death. Minor (defined as nonlife-threatening) and major peri-operative complication occurred respectively in 37% and 21% of the patients (Table 6) The median length of hospital stay was 9 days (range 4 to 30 days).
Post-operative platinum-based chemotherapy was administered in all patients; 221/240 (92%) were able to complete 5 or more cycles of platinum-based systematic chemotherapy (Table 4) .
On univariate analysis (Table 7) On multivariate analysis (Table 8) (Table 9) . At both the univariate and multivariate analysis the amount of ascites (< 1000 ml) and the absence of carcinomatosis were significantly associated with optimal residual disease. Age, ASA class and CA125 grater than 750 U/mL failed to achieve a statistical significance.
After a median follow up of 29.8 months, the overall median survival (OS) and progression free survival (PFS) were 61.1 and 20.4 months respectively (Fig. 2,3 ). safely. This initial observation has been confirmed by multiple subsequent studies and it became the current treatment paradigm for patients with advanced ovarian cancer [36, 50] . Therefore, the importance of a surgical cytoreduction in advanced ovarian cancer has become crucial, the debate over the definition of "optimal"
versus "suboptimal" primary cytoreducion still remains objective of argument within the scientific community. The current definition of "optimal cytoreduction" was established in 1991 by the GOG in Protocol 97 as residual tumor ≤ 1 cm [23] . The definition of optimal cytoreduction has remained ≤1 cm in all subsequent GOG protocols. Nonetheless, very recent international cooperative studies have continued to use different definitions of "optimal" cytoreduction, indicating a lack of common consensus [51, 52] .
Recently several reports have demonstrated that there may be an additional survival advantage associated with cytoreduction to no visible residual disease [29] [30] [31] [32] [33] [34] .
Bristow et al. evaluated 81 studies involving 6885 patients
and demonstrated that each 10% increase in the number of patients receiving maximal cytoreduction was associated with a 5.5% increase in median survival [36] Several authors showed that the use of extensive upper abdominal surgical procedures significantly increased the optimal primary cytoreduction with a significant impact on the overall survival of these patients [53, 54] . to the EORTC study. The low rate (46%, ≤ 1 cm) of optimal residual disease at the end of surgery in PDS group has significantly worsened the prognosis of these patients.
Moreover we looked at the correlation between different variables and the rate of no evidence of macroscopic disease at the end of primary cytoreductive surgery. Patients with ascites >1000 ml and with peritoneal carcinomatosis were less likely to be optimally debulked suggesting that these factors could represent pre-operative selecting criteria for patients who might benefit from adjuvant chemotherapy approach.
Our study displays few weaknesses of our study are: this is a single-institution retrospective study, the post operative management after primary therapy was not perfectly homogenous and the follow-up interval is modest.
Moreover few patients during the first two years of the study (2001) (2002) were treated prior to the implementation of upper abdominal surgery.
CONCLUSION
Our study seems to demonstrate that a more extensive surgical approach is associated with improved survival in patients with stages IIIC-IV epithelial ovarian cancer. Age grater than 60 years and residual tumor grater than 5 mm were independently associated with a worse prognosis. All patients with residual tumor ≤ 5 mm had the best prognosis as shown by the survival curves.
In view of these results we believe that the goal of primary surgery should be considered as leaving no macroscopic tumor or at least between 1-5 mm.
However in view of these findings gynaecologic oncologists must select carefully patients with advanced ovarian cancer and if complete gross resection is not feasible other therapeutic options must be considered. Future research should be directed at refining this model to more effectively stratify patients by likelihood of optimal resection, taking into account underlying health status and tumor dissemination (53) 98 (41) 11 ( 7 (3) 7 (3) 17 (7) 12 ( 
